Critical Limb Ischemia Rapid Delivery by SurgWerks-CLI Kit and VXP System
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 224 participants.
Also called NCT02538978
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 224 participants
- Sponsor
- Cesca Therapeutics, Inc.
- Registry
-
NCT02538978
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT02538978. Randomized; quadruple masking; primary purpose treatment. Start 2017-01 (registry gives no type); primary completion 2018-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Critical Limb Ischemia Rapid Delivery by SurgWerks-CLI Kit and VXP System
- Acronym
- CLIRST III
- Condition
- Critical Limb Ischemia (CLI)
- Intervention (Biological)
- Autologous Bone Marrow Concentrate (aBMC)
- Intervention (Biological)
- Placebo Control (diluted autologous peripheral blood)
- Lead sponsor
- Cesca Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct02538978- Content hash
c6152b05f3bcff0213cfc5a89abeecf9bc4da9d0c321ec47067189a6c84f4889